Patent – Validity. The claimant company issued proceedings to invalidate the defendant company's patents concerning a dosage regimen and composition of a monoclonal antibody called trastuzumab, a major breakthrough in *** cancer therapy. The Patents Court held that the patents were invalid. The patent concerning the dosage regimen was obvious in the light of the state of the art, and the patent concerning composition was anticipated and lacked inventive step.